Key result
Robotic mitral valve replacement shows no benefit over conventional sternotomy for 5-year mortality.
Why the study?
The study was conducted to compare early and medium-term outcomes between robotic and sternotomy approaches for mitral valve replacement.
Does robotic mitral valve replacement improve early and medium-term outcomes compared to conventional sternotomy in patients undergoing MVR?
Cohort (n=1,393)
No
Does robotic mitral valve replacement improve early and medium-term outcomes compared to conventional sternotomy in patients undergoing MVR?
Hazard Ratio: 0.831 (95% CI 0.388–1.777)
Absolute Event Rate: 5.4% vs 6.5%
p-value: p=0.633
Robotic mitral valve replacement is a safe and feasible alternative to conventional sternotomy, offering similar medium-term clinical outcomes with potential benefits in reduced ICU stay and blood loss.
This Level 3 evidence should not yet change practice; leaves open whether RCTs confirm early recovery benefits.
Background To compare early and medium-term outcomes between robotic and sternotomy approaches for mitral valve replacement (MVR). Methods Clinical data of 1393 cases who underwent MVR between January 2014 and January 2023 were collected and stratified into robotic MVR (n = 186) and conventional sternotomy MVR (n = 1207) groups. The baseline data of the two groups of patients were corrected by the propensity score matching (PSM) method. Results After matching, the baseline characteristics were not significant different between the two groups (standardized mean difference < 10%). Moreover, the rates of operative mortality (P = 0.663), permanent stroke (P = 0.914), renal failure (P = 0.758), pneumonia (P = 0.722), and reoperation (P = 0.509) were not significantly different. Operation, CPB and cross-clamp time were shorter in the sternotomy group. On the other hand, ICU stay time, post-operative LOS, intraoperative transfusion, and intraoperative blood loss were shorter or less in the robot group. Operation, CPB, and cross-clamp time in robot group were all remarkably improved with experience. Finally, all-cause mortality (P = 0.633), redo mitral valve surgery (P = 0.739), and valve-related complications (P = 0.866) in 5 years of follow-up were not different between the two groups. Conclusions Robotic MVR is safe, feasible, and reproducible for carefully selected patients with good operative outcomes and medium-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2023) conducted a cohort in Mitral valve disease (n=1,393). Robotic mitral valve replacement vs. Conventional sternotomy mitral valve replacement was evaluated on 5-year all-cause mortality (HR 0.831, 95% CI 0.388-1.777, p=0.633). Robotic mitral valve replacement showed no significant difference in 5-year all-cause mortality compared to conventional sternotomy (HR 0.831).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: